This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Switching antidepressant (tricyclic antidepressants (TCA) to vortioxetine) in adults

Authoring team

Switching antidepressant (tricyclic antidepressants (TCA) to vortioxetine)

There is limited experience with this switch so extra caution is required to avoid serotonin syndrome.

From all except clomipramine

Cross-taper

Cross-tapering can usually be undertaken cautiously over 2 to 4 weeks, the speed is determined by individual tolerability. It should include:

  • halving the dose of the TCA
  • then adding vortioxetine
  • then slowly reducing and stopping the TCA

Taper, washout and switch

  • alternatively, gradually reduce the dose of the TCA and stop; wait for a period before starting vortioxetine.
  • clinicians should decide the duration of the washout period on a case-by-case basis

From clomipramine

  • cross-tapering is not recommended and should only be undertaken if specialist advice is in place, this is because clomipramine is a potent serotonin reuptake inhibitor so there is a high risk of serotonin syndrome

Taper, stop and switch

  • if switching from clomipramine, gradually reduce the dose of clomipramine and stop
  • start low dose vortioxetine the following day

Taper, washout and switch

  • alternatively, gradually reduce the dose of clomipramine and stop; wait for a period before starting vortioxetine. Clinicians should decide the duration of the washout period on a case-by-case basis.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.